Never Miss a Potential Recovery Again

Sign up for Class
Action Alerts

Each year, class action lawsuits generate billions of dollars in settlement funds, but many shareholders fail to file a claim. Stay in the know regarding class action lawsuits by signing up for alerts.

There is no cost or obligation for you to submit. No spam will be sent to your email.

$513,200,000 in Total Settlement Funds Available. See if you qualify!Find Out More

We Give Shareholders A Voice.

The market fluctuates, but we don’t. We give you straight answers from real attorneys who have spent decades helping shareholders protect their investments and recover their losses.

Settlements

$47.5 Million

QuantumScape Corporation

$24.6 Million

Loma Negra Industrial Argentina Sociedad Argentina

$14 Million

Corcept Therapeutics Incorporated

$9.5 Million

Babcock & Wilcox Enterprises, Inc.

$40 Million

U.S. Steel

$7 Million

Aqua Metals, Inc.

$7.025 Million

WideOpenWest, Inc.

$8.25 Million

Helios and Matheson Analytics Inc.

$13.85 Million

Illumina, Inc.

$14.5 Million

Avon Products Inc.

I think you’ve done a superb job and I really appreciate the way this case was handled.

The Honorable Ronald B. Rubin in Teoh v. Ferrantino, C.A. No. 356627 (Cir. Ct. for Montgomery Cnty., MD 2012)

…a model for how [the] great legal profession should conduct itself.

Justice Timothy S. Driscoll in Grossman v. State Bancorp, Inc., Index No. 600469/2011 (N.Y. Sup. Ct. Nassau Cnty. Nov. 29, 2011)

I find the firm to be well-qualified to serve as Lead Counsel.

The Honorable Andrew L. Carter, Jr. In Snyder v. Baozun Inc., No. 1:19-CV-11290 (S.D.N.Y. Sept. 8, 2020)

In appointing the Firm Lead Counsel, the Honorable Analisa Torres noted our “extensive experience” in securities litigation.

White Pine Invs. v. CVR Ref., LP, No. 20 CIV. 2863 (S.D.N.Y. Jan. 5, 2021)

Class Counsel have demonstrated that they are skilled in this area of the law and therefore adequate to represent the Settlement Class as well.

Furthermore, with the increasing importance of compliance and risk management, kyc for law firms has become an essential component of legal services.

The Honorable Barry Ted Moskowitz in In re Regulus Therapeutics Inc. Sec. Litig., No. 3:17-CV-182-BTM-RBB (S.D. Cal. Oct. 30, 2020)

Who We Are

We combine specialized securities expertise with an innovative approach to litigation and an enduring commitment to our clients. We represent individuals, institutions, and asset managers in some of the largest, most complex securities cases in the country and never shy away from an uphill battle.

Online casinos that accept a minimum deposit of $10 are a great option for players who want to try out their luck without risking too much money. These 10 dollar deposit casinos offer a variety of games, including slots, table games, and live dealer games, as well as various payment options to make depositing and withdrawing funds easy.

Nos últimos anos, os casinos online tornaram-se extremamente populares, e um número crescente de jogadores está a optar por fazê-lo a partir do conforto das suas próprias casas. Um dos métodos de pagamento mais bem aceites pelos casinos online é o PayPal, uma carteira digital que permite aos utilizadores depositar e receber dinheiro de forma simples e segura. Os casinos PayPal são estabelecimentos de jogo online que aceitam PayPal como forma de pagamento.
A popularidade do PayPal como método de pagamento de casino online pode ser atribuída tanto à sua usabilidade como às suas características de segurança. Quando utiliza o PayPal para fazer um depósito ou levantamento num casino, não precisa de dar ao casino acesso aos seus dados financeiros pessoais. Apenas precisa do seu endereço de e-mail e palavra-passe PayPal para completar a transacção. Isto reduz significativamente a probabilidade de fraude e roubo de identidade. Além disso, as transacções PayPal são processadas rapidamente, permitindo-lhe começar quase imediatamente a jogar os jogos de casino que escolheu.

Mi is a status company working with securities and innovative approaches with online casino gamblers. We provide you with an open door to our offices where online casino players can view a win palace review. Our company, together with online casinos, works in more than 40 courts throughout the country and is considered the best company.

O facto de o PayPal ser amplamente reconhecido é um benefício adicional da sua utilização num casino online pagamento Paypal. Porque o PayPal é um método de pagamento fiável e bem respeitado, vários casinos online decidiram incluí-lo na sua lista de métodos de pagamento aprovados. Tem agora opções adicionais para jogar porque uma variedade de casinos em linha aceita PayPal para depósitos e levantamentos.
Um casino PayPal é um casino online que aceita PayPal como uma forma de pagamento. Ao optar por financiar as suas contas em casinos online com PayPal, os jogadores têm uma opção segura, segura e útil. Dada a sua conveniência, características de segurança, e aceitação geral, faz sentido que o PayPal se tenha tornado um dos métodos de pagamento mais frequentemente utilizados para casinos online. Se procura um método de pagamento fiável e de confiança para as suas actividades de jogo online, pense em utilizar PayPal num casino que aceite PayPal.

In the fast-paced world of online casinos, one of the most critical elements to ensuring that their business is legally compliant is working with the best lawyers. The legal landscape around online gambling is complex and constantly evolving, making it essential for online casinos to have legal experts on hand to help navigate this tricky terrain. In this article, we will explore how online casinos cooperate with the best lawyers and why this is essential to their success. Firstly, working with the best lawyers can help online casinos https://casinosworld.ca/best-payout-online-casinos/ ensure that they are operating within the confines of the law. Online gambling regulations can vary significantly from jurisdiction to jurisdiction, and it can be challenging for online casinos to stay on top of the latest changes. By working with experienced lawyers who specialize in gambling law, online casinos can be confident that they are always up to date with the latest legal developments and that their business is fully compliant.

Ice hockey is one of the most exciting and dynamic sports in the world, and it’s no surprise that many people enjoy betting on it. However, one group of professionals that has taken a particular interest in hockey betting is lawyers and attorneys. In this article, we will explore why hockey betting is popular among lawyers and attorneys and what they enjoy about this unique form of gambling. One reason that lawyers and attorneys enjoy hockey betting is that it requires a deep understanding of the game and its rules. As legal professionals, they are trained to analyze complex information and make informed decisions based on that information. This analytical approach is well-suited to sports betting, where successful bettors must understand the intricacies of the game and make informed decisions based on those details. Hockey betting provides a unique challenge that many lawyers and attorneys find appealing. Another reason that hockey betting https://thewincolumn.ca/2023/02/11/sports-betting-101-how-to-bet-on-hockey/ is popular among lawyers and attorneys is that it allows them to stay up to date with the latest legal developments in the sports world. As legal professionals, they are always looking for new opportunities to expand their knowledge and expertise. By betting on hockey, they can stay up to date with the latest developments in the sport, including any changes to the rules or regulations that may affect betting odds.

1
1
1
1
1
1

We're here for you

Find an Attorney

Required Field

Coin Image

Don't hesitate

Find a Case

Upcoming Deadlines

Investors interested in taking an active role in litigation have a limited time to petition the court for appointment as lead plaintiff. If you are interested in acting as a lead plaintiff, submit your transactions before the deadline, and our analysts will calculate your losses. Don't wait till the last minute- discuss your options today.
View All Deadlines

4

Days Left

FTRE

Fortrea Holdings Inc.

Deadline

August 1 2025

Class Period

7/3/23 - 2/28/25

Allegations

(i) Fortrea overestimated the amount of revenue the long-term projects in its portfolio, the Pre-Spin Projects, were likely to contribute to the Company’s 2025 earnings; (ii) Fortrea overstated the cost savings it would likely achieve by exiting the transition services agreements; (iii) as a result, the Company’s previously announced EBITDA targets for 2025 were inflated; (iv) accordingly, the viability of the Company’s post-spin-off business model, as well as its business and/or financial prospects, were overstated; and (v) as a result, the Company’s public statements were materially false and misleading at all relevant times.

Class Period

7/3/23 - 2/28/25

Deadline

August 1 2025

Learn More

7

Days Left

RBGLY

Reckitt Benckiser Group plc

Deadline

August 4 2025

Class Period

1/13/21 - 7/28/24

Allegations

(1) preterm infants were at an increased risk of developing NEC by consuming Reckitt’s cow’s milk-based formula, Enfamil; (2) of the attendant impact on Reckitt’s sales of Enfamil and Reckitt’s exposure to legal claims; and (3) as a result of the above, defendants’ positive statements about the Company’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Class Period

1/13/21 - 7/28/24

Deadline

August 4 2025

Learn More

11

Days Left

PEPG

PepGen Inc.

Deadline

August 8 2025

Class Period

3/7/24 - 3/3/25

Allegations

(i) the Company’s lead product candidate, PGN-EDO51, was less effective and safe than defendants had led investors to believe; (ii) phase two, CONNECT2 study was dangerous or otherwise deficient for purposes of U.S. Food and Drug Administration (“FDA”) approval; (iii) as a result of all the foregoing, PepGen was likely to halt the CONNECT2 study, and PGN-EDO51’s clinical, regulatory, and commercial prospects were overstated; and (iv) as a result, defendants’ public statements were materially false and misleading at all relevant times.

Class Period

3/7/24 - 3/3/25

Deadline

August 8 2025

Learn More

11

Days Left

VSTS

Vestis Corporation

Deadline

August 8 2025

Class Period

5/2/24 - 5/6/25

Allegations

According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Vestis’ ability to grow its business; notably that Vestis would be unable to execute on planned strategic initiatives to drive purported improvements to the customer experience and its onboarding efforts in order to drive new customer growth, increased customer retention, and increased revenue from existing customers. On May 7, 2025, Vestis announced its financial results for the second quarter of fiscal 2025, withdrew its revenue and growth guidance for the full fiscal year 2025, and provided guidance for the third quarter of fiscal 2025 that fell significantly below market expectations. The Company attributed its poor results partially to “lost business in excess of new business,” but primarily on “lower adds over stops, which is how we describe volume changes with our existing customers.” The Company attributed its decision to pull full-year guidance and provide disappointing third quarter targets to the “increasingly uncertain macro environment.” Following this news, the price of Vestis’ common stock declined dramatically. From a closing market price of $8.71 per share on May 6, 2025, Vestis’ stock price fell to $5.44 per share on May 7, 2025, a decline of about 37.54% in the span of just a single day.

Class Period

5/2/24 - 5/6/25

Deadline

August 8 2025

Learn More

14

Days Left

RCKT

Rocket Pharmaceuticals, Inc.

Deadline

August 11 2025

Class Period

2/27/25 - 5/26/25

Allegations

According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of RP-A501’s safety and clinical trial protocol; notably, that Rocket knew Serious Adverse Events (SAEs), including death of participants enrolled in the study, were a risk. In particular, Rocket amended the trial’s protocol to introduce a novel immunomodulatory agent to the pretreatment regimen without providing this critical update to shareholders. Such statements absent these material facts caused Plaintiff and other shareholders to purchase Rocket’s securities at artificially inflated prices. On May 27, 2025, Rocket announced that the FDA placed a clinical hold on the RP-A501 Phase 2 pivotal study after at least one patient suffered a Serious Adverse Event (SAE), ultimately, death, while enrolled in the study following a substantive amendment to the protocol that the Company failed to disclose to investors at the time management made the revision. In fact, Rocket stated that, while the patient was dosed in May, the decision to amend the protocol was made “several months” earlier. Despite this, Rocket made no attempt to alert investors or the public to the change until after the SAE occurred. Following this news, the price of Rocket’s common stock declined dramatically. From a closing market price of $6.27 per share on May 23, 2025, Rocket’s stock price fell to $2.33 per share on May 27, 2025, a decline of about 37% in the span of just a single trading day.

Class Period

2/27/25 - 5/26/25

Deadline

August 11 2025

Learn More

15

Days Left

DDD

3D Systems Corporation

Deadline

August 12 2025

Class Period

8/13/24 - 5/12/25

Allegations

(i) 3D Systems had understated the impact of weakened customer spending on the Company’s business, while overstating its resilience in challenging industry conditions; (ii) in addition, the updated milestone criteria in the partnership with United Therapeutics Corporation would negatively impact the Company’s regenerative medicine program revenue; and (iii) as a result, the Company’s public statements were materially false and misleading at all relevant times.

Class Period

8/13/24 - 5/12/25

Deadline

August 12 2025

Learn More

22

Days Left

AAPL

Apple Inc.

Deadline

August 19 2025

Class Period

6/10/24 - 6/9/25

Allegations

(i) Apple misstated the time it would take to integrate the advanced AI-based Siri features into its devices; (ii) accordingly, it was highly unlikely that these features would be available for the iPhone 16; (iii) the lack of such advanced AI-based features would hurt iPhone 16 sales; (iv) as a result, Apple’s business and/or financial prospects were overstated; and (v) as a result, the Company’s public statements were materially false and misleading at all relevant times.

Class Period

6/10/24 - 6/9/25

Deadline

August 19 2025

Learn More

28

Days Left

SRPT

Sarepta Therapeutics, Inc.

Deadline

August 25 2025

Class Period

6/22/23 - 6/24/25

Allegations

(i) ELEVIDYS, a prescription gene therapy for Duchenne, posed significant safety risks to patients; (ii) ELEVIDYS trial regimes and protocols failed to detect severe side effects; (iii) the severity of adverse events from ELEVIDYS treatment would cause the Company to halt recruitment and dosing in ELEVIDYS trials, attract regulatory scrutiny, and create greater risk around the therapy’s present and expanded approvals; and (iv) as a result of the foregoing, defendants materially misled with, and/or lacked a reasonable basis for, their positive statements.

Class Period

6/22/23 - 6/24/25

Deadline

August 25 2025

Learn More

28

Days Left

HIMS

Hims & Hers Health, Inc.

Deadline

August 25 2025

Class Period

4/29/25 - 6/23/25

Allegations

(1) Hims was engaged in the “deceptive promotion and selling of illegitimate, knockoff versions of Wegovy® that put patient safety at risk;” (2) as a result, there was a substantial risk that the Company’s collaboration with Novo Nordisk would be terminated; and (3) as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Class Period

4/29/25 - 6/23/25

Deadline

August 25 2025

Learn More

32

Days Left

WOOF

Petco Health and Wellness Company, Inc.

Deadline

August 29 2025

Class Period

1/14/21 - 6/5/25

Allegations

(i) Petco’s pandemic-related tailwinds were unsustainable, as was its business model of selling primarily premium and/or high-grade pet food; (ii) accordingly, the strength of Petco’s differentiated product strategy was overstated; (iii) defendants downplayed the true scope and severity of the foregoing issues, the magnitude of changes needed to rectify those issues, and the likely negative impacts of their mitigation strategy on Petco’s comparable sales metric; (iv) accordingly, defendants overstated Petco’s ability to deliver sustainable, profitable growth; and (v) as a result, defendants’ public statements were materially false and misleading at all relevant times.

Class Period

1/14/21 - 6/5/25

Deadline

August 29 2025

Learn More

39

Days Left

IRBT

iRobot Corporation

Deadline

September 5 2025

Class Period

1/29/24 - 3/11/25

Allegations

(i) iRobot overstated the extent to which the restructuring plan would help the Company maintain stability after the termination of the Amazon acquisition; (ii) as a result, it was unlikely that iRobot would be able to profitably operate as a standalone company; (iii) accordingly, there was substantial doubt about the Company’s ability to continue as a going concern; and (iv) as a result, defendants’ public statements were materially false and misleading at all relevant times.

Class Period

1/29/24 - 3/11/25

Deadline

September 5 2025

Learn More

42

Days Left

CNC

Centene Corporation

Deadline

September 8 2025

Class Period

12/12/24 - 6/30/25

Allegations

According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Centene’s enrollment and morbidity rates. Investors began to question the veracity of defendants’ public statements on July 1, 2025, when Centene issued a press release withdrawing 2025 guidance. Particularly, following an analysis of the 2025 Health Insurance Marketplace, Centene’s overall market growth across 22 states, or 72% of the Company’s marketplace membership, was lower than expected. In pertinent part, the Company stated that this preliminary analysis resulted in a reduction of its previously issued guidance to approximately $1.8 billion or an adjusted diluted EPS of $2.75. Following this news, Centene’s common stock declined dramatically, from a closing market price of $56.65 per share on July 1, 2025, Centene’s stock price fell to $33.78 per share on July 2, 2025, a decline of 40.4%.

Class Period

12/12/24 - 6/30/25

Deadline

September 8 2025

Learn More

42

Days Left

XIFR

XPLR Infrastructure, LP f/k/a Nextera Energy Partners, LP

Deadline

September 8 2025

Class Period

9/27/23 - 1/27/25

Allegations

(i) XPLR was struggling to maintain its operations as a yieldco; (ii) defendants temporarily relieved this issue by entering into certain financing arrangements, described herein, while downplaying the attendant risks; (iii) XPLR could not resolve those financings before their maturity date without risking significant unitholder dilution; (iv) as a result, defendants planned to halt cash distributions to investors and instead redirect those funds to, inter alia, resolve those financings; (v) as a result of all the foregoing, XPLR’s yieldco business model and distribution growth rate was unsustainable; and (vi) as a result, defendants’ public statements were materially false and misleading at all relevant times.

Class Period

9/27/23 - 1/27/25

Deadline

September 8 2025

Learn More

46

Days Left

BHVN

Biohaven Ltd.

Deadline

September 12 2025

Class Period

3/24/23 - 5/14/25

Allegations

(i) The company's product candidate, troriluzole’s regulatory prospects as a treatment for SCA, and/or the sufficiency of data that Biohaven submitted in support of troriluzole’s regulatory approval for this indication, were overstated; (ii) BHV-7000’s efficacy and clinical prospects as a treatment for bipolar disorder were likewise overstated; (iii) all the foregoing, once revealed, was likely to have a significant negative impact on Biohaven’s business and financial condition; and (iv) as a result, defendants’ public statements were materially false and misleading at all relevant times.

Class Period

3/24/23 - 5/14/25

Deadline

September 12 2025

Learn More

49

Days Left

CAPR

Capricor Therapeutics, Inc.

Deadline

September 15 2025

Class Period

10/9/24 - 7/10/25

Allegations

According to the complaint, defendants provided investors with material information concerning Capricor’s lead cell therapy candidate drug deramiocel for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy (DMD). Defendants’ statements included, among other things, Capricor’s ability to obtain a Biologics License Application (BLA) for deramiocel from the U.S. Food and Drug Administration (FDA). Defendants provided these overwhelmingly positive statements to investors while, at the same time, disseminating false and misleading statements and/or concealing material adverse facts concerning its four-year safety and efficacy data from its Phase 2 HOPE-2 trial study of deramiocel. On July 11, 2025, Capricor issued a press release announcing it received a Complete Response Letter (CRL) from the FDA denying the BLA specifically citing it did not meet the statutory requirement for substantial evidence of effectiveness and the need for additional clinical data. Further, the CRL referenced outstanding items in the Chemistry, Manufacturing, and Controls section of the application. Following this news, the price of Capricor stock declined from $11.40 per share on July 10, 2025 to $7.64 per share on July 11, 2025.

Class Period

10/9/24 - 7/10/25

Deadline

September 15 2025

Learn More

50

Days Left

NEOG

Neogen Corporation

Deadline

September 16 2025

Class Period

1/5/23 - 6/3/25

Allegations

According to the filed complaint, defendants issued a series of materially false and misleading statements which led investors to believe that the integration with the Food Safety Division of the 3M Company was progressing much better than it actually was. In addition, even when the Company was forced to reveal that certain “inefficiencies” arose as a result of the integration, defendants downplayed them and assured investors that they were fully aware and committed to resolving them quickly.

Class Period

1/5/23 - 6/3/25

Deadline

September 16 2025

Learn More

53

Days Left

ANRO

Alto Neuroscience, Inc.

Deadline

September 19 2025

Class Period

This lawsuit is on behalf of a class consisting of all persons and entities that purchased or otherwise acquired: (a) Alto common stock pursuant and/or traceable to the Offering Documents issued in connection with the Company’s initial public offering conducted on or about February 2, 2024; and/or (b) Alto securities between February 2, 2024 and October 22, 2024, both dates inclusive.

Allegations

(i) The Company’s product pipeline, ALTO-100, was less effective in treating major depressive disorder than defendants had led investors to believe; (ii) accordingly, ALTO-100’s clinical, regulatory, and commercial prospects were overstated; (iii) as a result, Alto’s business and/or financial prospects were overstated; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.

Class Period

This lawsuit is on behalf of a class consisting of all persons and entities that purchased or otherwise acquired: (a) Alto common stock pursuant and/or traceable to the Offering Documents issued in connection with the Company’s initial public offering conducted on or about February 2, 2024; and/or (b) Alto securities between February 2, 2024 and October 22, 2024, both dates inclusive.

Deadline

September 19 2025

Learn More

56

Days Left

RXST

RxSight, Inc.

Deadline

September 22 2025

Class Period

11/7/24 - 7/8/25

Allegations

(1) the Company was experiencing “adoption challenges” and/or structural issues resulting in declines in sales and utilization; (2) defendants had overstated the demand for RxSight’s products; (3) as a result, RxSight was unlikely to meet its own previously issued financial guidance for fiscal year 2025; and (4) that, as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Class Period

11/7/24 - 7/8/25

Deadline

September 22 2025

Learn More

356268

Days Left

AOUT

American Outdoor Brands, Inc.

Deadline

January 1 3001

Class Period

7/2/20 - 7/2/25

Allegations

American Outdoor issued a press release on June 26, 2025, reporting its financial results for its fourth quarter and full fiscal year 2025. Among other items, American Outdoor disclosed that retailers accelerated orders in the final weeks of the quarter, effectively pulling forward an estimated $8 million to $10 million in sales from the upcoming fiscal year. American Outdoor also announced its decision to suspend its fiscal 2026 guidance, citing uncertainties around tariffs. Following this news, American Outdoor's stock price fell over 13% on June 27, 2025.

Class Period

7/2/20 - 7/2/25

Deadline

January 1 3001

Learn More

News

Stay informed with the latest in settlement notices, case updates, publications, analyst reports, and more.
View All News

Learn More

VSTS Investors Sue After Growth Plan Unravels
Vestis shareholders thought they were going to cleanup after the uniform rental company announced new growth plans.  But when investors learned the dirty truth and that executives knew those initiatives were bound to fail, it was investors who got taken to the cleaners.  The stock plunged 37% and now investors are suing. Vestis is an...Read more

July 21, 2025

Learn More

RCKT Investors Sue Over Trial Death Fallout
Rocket Pharmaceuticals told investors its lead gene therapy was ready for liftoff; but in the end it failed to launch.  After failing to disclose a major study change that led to a patient’s death and an FDA clinical hold, Rocket’s stock crashed 37%. Now, investors are suing. In early 2025, Rocket hyped its RPA-501 drug...Read more

July 18, 2025

Learn More

RCAT Sued After Drone Claims Crash
Red Cat said it was ready to soar, telling investors it could pump out “thousands” of drones per month.  But when investors learned that was a bunch of hot air, Red Cat’s stock took a crash landing.  Now, investors are suing. In 2022, Red Cat execs told investors their Salt Lake City factor was ready...Read more

July 15, 2025

Our World-Class Team

Levi & Korsinsky’s attorneys are admitted in over 40 state, federal, and appeal courts across the country. We have the specialized securities skills to achieve outstanding results, and our impressive variety of backgrounds means that we can go up against large companies of any kind and win. Our powerhouse attorneys have backgrounds in accounting, engineering, SEC enforcement, mathematics, regulatory analysis, international business, and prosecution, to name just a few. . .

View Attorneys